Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.39
RHHVF's Cash to Debt is ranked lower than
89% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. RHHVF: 0.39 )
Ranked among companies with meaningful Cash to Debt only.
RHHVF' s Cash to Debt Range Over the Past 10 Years
Min: 0.36  Med: 1.51 Max: N/A
Current: 0.39
Equity to Asset 0.28
RHHVF's Equity to Asset is ranked lower than
85% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RHHVF: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
RHHVF' s Equity to Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.38 Max: 0.59
Current: 0.28
0.1
0.59
Interest Coverage 16.00
RHHVF's Interest Coverage is ranked lower than
78% of the 369 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RHHVF: 16.00 )
Ranked among companies with meaningful Interest Coverage only.
RHHVF' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 10.84 Max: N/A
Current: 16
F-Score: 5
Z-Score: 3.59
M-Score: -2.86
WACC vs ROIC
6.33%
30.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 27.42
RHHVF's Operating margin (%) is ranked higher than
90% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. RHHVF: 27.42 )
Ranked among companies with meaningful Operating margin (%) only.
RHHVF' s Operating margin (%) Range Over the Past 10 Years
Min: 24  Med: 28.74 Max: 35.01
Current: 27.42
24
35.01
Net-margin (%) 17.58
RHHVF's Net-margin (%) is ranked higher than
87% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. RHHVF: 17.58 )
Ranked among companies with meaningful Net-margin (%) only.
RHHVF' s Net-margin (%) Range Over the Past 10 Years
Min: 15.22  Med: 18.73 Max: 23.86
Current: 17.58
15.22
23.86
ROE (%) 46.10
RHHVF's ROE (%) is ranked higher than
98% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. RHHVF: 46.10 )
Ranked among companies with meaningful ROE (%) only.
RHHVF' s ROE (%) Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 46.1
19.94
102.95
ROA (%) 12.07
RHHVF's ROA (%) is ranked higher than
92% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. RHHVF: 12.07 )
Ranked among companies with meaningful ROA (%) only.
RHHVF' s ROA (%) Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.07
10.33
17.58
ROC (Joel Greenblatt) (%) 64.53
RHHVF's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. RHHVF: 64.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RHHVF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 51.65  Med: 64.13 Max: 84.52
Current: 64.53
51.65
84.52
Revenue Growth (3Y)(%) 3.20
RHHVF's Revenue Growth (3Y)(%) is ranked lower than
51% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. RHHVF: 3.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RHHVF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.7  Med: 5.20 Max: 394
Current: 3.2
-3.7
394
EBITDA Growth (3Y)(%) -0.40
RHHVF's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. RHHVF: -0.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RHHVF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.8  Med: 16.50 Max: 322.9
Current: -0.4
-2.8
322.9
EPS Growth (3Y)(%) -2.70
RHHVF's EPS Growth (3Y)(%) is ranked higher than
53% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. RHHVF: -2.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RHHVF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.7  Med: 8.60 Max: 340.9
Current: -2.7
-3.7
340.9
» RHHVF's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with RHHVF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:NVO, NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB, OTCPK:CSLLY, NAS:REGN, NAS:SHPG, NYSE:BXLT, NAS:ALXN, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, OTCPK:UCBJF, OTCPK:NVZMY, NAS:BMRN, NAS:GRFS, OTCPK:GMXAY, NAS:MDVN, NAS:JAZZ » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Ratios

vs
industry
vs
history
P/E(ttm) 25.14
RHHVF's P/E(ttm) is ranked higher than
60% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 29.12 vs. RHHVF: 25.14 )
Ranked among companies with meaningful P/E(ttm) only.
RHHVF' s P/E(ttm) Range Over the Past 10 Years
Min: 13.05  Med: 19.74 Max: 37.26
Current: 25.14
13.05
37.26
Forward P/E 16.42
RHHVF's Forward P/E is ranked higher than
66% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 20.62 vs. RHHVF: 16.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.14
RHHVF's PE(NRI) is ranked higher than
60% of the 230 Companies
in the Global Biotechnology industry.

( Industry Median: 28.93 vs. RHHVF: 25.14 )
Ranked among companies with meaningful PE(NRI) only.
RHHVF' s PE(NRI) Range Over the Past 10 Years
Min: 13.04  Med: 19.63 Max: 37.08
Current: 25.14
13.04
37.08
Price/Owner Earnings (ttm) 17.76
RHHVF's Price/Owner Earnings (ttm) is ranked higher than
70% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 32.52 vs. RHHVF: 17.76 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RHHVF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.69  Med: 15.32 Max: 29.45
Current: 17.76
9.69
29.45
P/B 10.50
RHHVF's P/B is ranked lower than
84% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. RHHVF: 10.50 )
Ranked among companies with meaningful P/B only.
RHHVF' s P/B Range Over the Past 10 Years
Min: 2.64  Med: 11.32 Max: 22.21
Current: 10.5
2.64
22.21
P/S 4.43
RHHVF's P/S is ranked higher than
72% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. RHHVF: 4.43 )
Ranked among companies with meaningful P/S only.
RHHVF' s P/S Range Over the Past 10 Years
Min: 2.33  Med: 4.08 Max: 6.05
Current: 4.43
2.33
6.05
PFCF 20.00
RHHVF's PFCF is ranked higher than
67% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 26.54 vs. RHHVF: 20.00 )
Ranked among companies with meaningful PFCF only.
RHHVF' s PFCF Range Over the Past 10 Years
Min: 8.71  Med: 17.25 Max: 36.73
Current: 20
8.71
36.73
POCF 14.64
RHHVF's POCF is ranked higher than
68% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 22.98 vs. RHHVF: 14.64 )
Ranked among companies with meaningful POCF only.
RHHVF' s POCF Range Over the Past 10 Years
Min: 7.05  Med: 13.70 Max: 21.96
Current: 14.64
7.05
21.96
EV-to-EBIT 17.93
RHHVF's EV-to-EBIT is ranked higher than
58% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 22.57 vs. RHHVF: 17.93 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHVF' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13.80 Max: 24.3
Current: 17.93
7.8
24.3
EV-to-EBITDA 13.94
RHHVF's EV-to-EBITDA is ranked higher than
61% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. RHHVF: 13.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHVF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.5  Med: 11.80 Max: 21.8
Current: 13.94
6.5
21.8
PEG 15.93
RHHVF's PEG is ranked lower than
90% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. RHHVF: 15.93 )
Ranked among companies with meaningful PEG only.
RHHVF' s PEG Range Over the Past 10 Years
Min: 0.27  Med: 1.68 Max: 18.57
Current: 15.93
0.27
18.57
Shiller P/E 23.03
RHHVF's Shiller P/E is ranked higher than
83% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 51.02 vs. RHHVF: 23.03 )
Ranked among companies with meaningful Shiller P/E only.
RHHVF' s Shiller P/E Range Over the Past 10 Years
Min: 18.47  Med: 23.86 Max: 35.38
Current: 23.03
18.47
35.38
Current Ratio 1.19
RHHVF's Current Ratio is ranked lower than
86% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. RHHVF: 1.19 )
Ranked among companies with meaningful Current Ratio only.
RHHVF' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 2.37 Max: 3.75
Current: 1.19
1.19
3.75
Quick Ratio 0.86
RHHVF's Quick Ratio is ranked lower than
86% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. RHHVF: 0.86 )
Ranked among companies with meaningful Quick Ratio only.
RHHVF' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.97 Max: 3.22
Current: 0.86
0.86
3.22
Days Inventory 179.07
RHHVF's Days Inventory is ranked lower than
66% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. RHHVF: 179.07 )
Ranked among companies with meaningful Days Inventory only.
RHHVF' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 159.24 Max: 186.16
Current: 179.07
143.33
186.16
Days Sales Outstanding 60.32
RHHVF's Days Sales Outstanding is ranked higher than
53% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. RHHVF: 60.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHVF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.32  Med: 74.15 Max: 84.09
Current: 60.32
60.32
84.09
Days Payable 75.72
RHHVF's Days Payable is ranked higher than
60% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 59.87 vs. RHHVF: 75.72 )
Ranked among companies with meaningful Days Payable only.
RHHVF' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 60.53 Max: 78.64
Current: 75.72
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.13
RHHVF's Dividend Yield is ranked higher than
88% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. RHHVF: 3.13 )
Ranked among companies with meaningful Dividend Yield only.
RHHVF' s Dividend Yield Range Over the Past 10 Years
Min: 0.99  Med: 2.88 Max: 4.55
Current: 3.13
0.99
4.55
Dividend Payout 0.78
RHHVF's Dividend Payout is ranked lower than
86% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. RHHVF: 0.78 )
Ranked among companies with meaningful Dividend Payout only.
RHHVF' s Dividend Payout Range Over the Past 10 Years
Min: 0.21  Med: 0.55 Max: 0.78
Current: 0.78
0.21
0.78
Dividend Growth (3y) 5.60
RHHVF's Dividend Growth (3y) is ranked lower than
54% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 8.70 vs. RHHVF: 5.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
RHHVF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 10.80 Max: 27.3
Current: 5.6
0
27.3
Forward Dividend Yield 3.18
RHHVF's Forward Dividend Yield is ranked higher than
87% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. RHHVF: 3.18 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.24
RHHVF's Yield on cost (5-Year) is ranked higher than
85% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 1.46 vs. RHHVF: 4.24 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RHHVF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.32  Med: 3.84 Max: 6.06
Current: 4.24
1.32
6.06
3-Year Average Share Buyback Ratio 0.40
RHHVF's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.40 vs. RHHVF: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHVF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 78.5
Current: 0.4
0
78.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.68
RHHVF's Price/Projected FCF is ranked higher than
77% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. RHHVF: 1.68 )
Ranked among companies with meaningful Price/Projected FCF only.
RHHVF' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.12  Med: 1.73 Max: 3.64
Current: 1.68
1.12
3.64
Price/Median PS Value 1.06
RHHVF's Price/Median PS Value is ranked lower than
59% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. RHHVF: 1.06 )
Ranked among companies with meaningful Price/Median PS Value only.
RHHVF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.63  Med: 1.00 Max: 1.3
Current: 1.06
0.63
1.3
Earnings Yield (Greenblatt) (%) 5.53
RHHVF's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. RHHVF: 5.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RHHVF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.1  Med: 7.20 Max: 12.8
Current: 5.53
4.1
12.8
Forward Rate of Return (Yacktman) (%) 7.07
RHHVF's Forward Rate of Return (Yacktman) (%) is ranked lower than
61% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.46 vs. RHHVF: 7.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RHHVF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.6  Med: 13.90 Max: 112.1
Current: 7.07
4.6
112.1

More Statistics

Revenue (TTM) (Mil) $52,253
EPS (TTM) $ 10.74
Beta0.57
Short Percentage of Float0.00%
52-Week Range $238.95 - 302.43
Shares Outstanding (Mil)852.02

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 43,473 46,489 53,037
EPS ($) 12.75 13.79 16.32
EPS w/o NRI ($) 12.75 13.79 16.32
EPS Growth Rate
(3Y to 5Y Estimate)
8.66%
» More Articles for RHHVF

Headlines

Articles On GuruFocus.com
Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Invesco European Growth Fund Adds to More Than 40 Existing Stakes Apr 04 2016 
Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 

More From Other Websites
Roche's Multiple Sclerosis Drug Under Review by FDA, EMA Jun 29 2016
What Were Roche’s Breakthrough Therapy Designations in 2016? Jun 28 2016
What Were Roche’s Breakthrough Therapy Designations in 2015? Jun 28 2016
Roche anticipates quicker U.S. approval for new MS drug Jun 28 2016
Roche Holding AG breached its 50 day moving average in a Bearish Manner : RHHVF-US : June 27, 2016 Jun 27 2016
How Did Roche’s Diagnostics Division Perform? Jun 25 2016
How Was Roche’s Operational Performance in 2Q16? Jun 25 2016
Why Is Roche Trading at a Discount? Jun 23 2016
What Does Roche’s Valuation Indicate? Jun 23 2016
Roche CEO 'sleeps better' as risk to drugmaker's growth recedes Jun 22 2016
Roche CEO 'sleeps better' as risk to drugmaker's growth recedes Jun 22 2016
Roche Holding AG – Value Analysis (US OTC:RHHVF) : June 20, 2016 Jun 20 2016
[$$] Brexit or Not, Adidas and Roche Offer Solid Returns Jun 17 2016
Roche Holding AG breached its 50 day moving average in a Bearish Manner : RHHVF-US : June 14, 2016 Jun 14 2016
Roche Presents Encouraging Data on Actemra and Tecentriq Jun 06 2016
Study finds targeted cancer drugs may work in range of tumor types Jun 06 2016
Combination Drug Therapies for Cancer Show Promise at Higher Potential Cost Jun 05 2016
Roche therapy helps 24 pct of untreated bladder cancer patients-study Jun 05 2016
Study finds targeted cancer drugs may work in range of tumor types Jun 04 2016
Study Finds Mylan’s ‘Biosimilar’ Drug Comparable to Roche Cancer Medicine Jun 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)